Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks. Cells ...
The TCR repertoire provides a novel platform for investigating the modulation of the TME post-TACE and the underlying mechanisms governing tumor development and recurrence. Clarifying the distinctive ...
Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...
Chimeric antigen receptor (CAR)-T cells and T-cell therapies have been used in the treatment of various cancers for several years. In a review published in JAMA, a research team led by Christian ...
Secondary primary malignancies (SPMs) with CAR-T cell therapy in RR-DLBCL from real-world data. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a ...
TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor (TCR) therapy biotech abandons a phase 1 solid tumor trial and focuses on patients with blood cancers. The company had ...
Captain T Cell GmbH has successfully closed an equity financing round to support its T-cell receptor (TCR) T-cell therapies for solid tumors. The company’s autologous lead program, CTC-127, is a ...
Chimeric antigen receptor (CAR) T-cell therapy has shown efficacy in blood cancers — with six CAR T-cell products now approved by the US Food and Drug Administration (FDA) to treat six hematologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback